MK-3475 (SCH 9000475) as neoadjuvant and adjuvant therapy in Stage III-IVA resectable

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Stage Iii-iva Resectable Locoregionally Advanced Head And Neck Squamous Cell Carcinoma (la Hnscc)
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Have histologically confirmed new diagnosis of resectable, non-metastatic, squamous cell carcinoma as assessed by the investigator based on baseline imaging and clinical assessment that is either: a. Stage III oropharyngeal p16 positive that is T4 (N0-N2), M0 OR b. Stage III or IVA oropharyngeal p16 negative OR c. Stage III or IVA larynx/hypopharynx/oral cavity (independent of p16). 2) Be eligible for primary surgery based on investigator decision and per local practice.

You may not be eligible for this study if the following are true:

  • 1. Has Stage T4B and/or N3 LA HNSCC and/or distant metastases. 2. Has cancer outside of the oropharynx, larynx, and hypopharynx or oral cavity, such as nasopharyngeal, sinus, other para-nasal, or other unknown primary HNC. 3. A WOCBP who has a positive urine pregnancy test within 72 hours prior to randomization or within 24 hours prior to the start of RT with or without cisplatin

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.